LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

17.47 0.58

Visão Geral

Variação de preço das ações

24h

Atual

Mín

17.35

Máximo

17.66

Indicadores-chave

By Trading Economics

Rendimento

6M

Vendas

162M

P/E

Médio do Setor

6.079

35.664

EPS

0.52

Margem de lucro

3.676

Funcionários

1,780

EBITDA

-5M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+43.35% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.8B

Abertura anterior

16.89

Fecho anterior

17.47

Sentimento de Notícias

By Acuity

50%

50%

185 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de set. de 2025, 17:03 UTC

Grandes Movimentos do Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 de set. de 2025, 16:49 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

GD Culture Shares Drop After Deal for Pallas Capital

16 de set. de 2025, 16:11 UTC

Grandes Movimentos do Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 de set. de 2025, 23:40 UTC

Conversa de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 de set. de 2025, 23:34 UTC

Conversa de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 de set. de 2025, 23:20 UTC

Conversa de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 de set. de 2025, 21:10 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 de set. de 2025, 20:51 UTC

Conversa de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 20:25 UTC

Ganhos

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 de set. de 2025, 20:24 UTC

Ganhos

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 de set. de 2025, 19:19 UTC

Conversa de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 de set. de 2025, 18:52 UTC

Conversa de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 de set. de 2025, 18:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 de set. de 2025, 18:38 UTC

Conversa de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 de set. de 2025, 18:19 UTC

Conversa de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 18:01 UTC

Conversa de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 de set. de 2025, 17:34 UTC

Conversa de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 de set. de 2025, 16:53 UTC

Ganhos

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 de set. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 16:15 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Commodities Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Energy Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 15:22 UTC

Conversa de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 de set. de 2025, 15:21 UTC

Conversa de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

43.35% parte superior

Previsão para 12 meses

Média 25 USD  43.35%

Máximo 25 USD

Mínimo 25 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

14.24 / 14.78Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

185 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat